Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.

**Synonyms:** - Ad26-expressing HPV18 Vaccine JNJ-63682931 - Ad26.HPV18 JNJ-63682931 - Adenovirus Serotype 26-Human Papillomavirus 18 JNJ-63682931 - JNJ 63682931 - JNJ-63682931 - JNJ63682931 - Monovalent HPV18 Ad26-vectored Vaccine JNJ-63682931